Adeno-Associated Virus (AAV)

Adeno-Associated Virus (AAV) is a small, non-pathogenic virus widely employed as a delivery vehicle in gene therapy applications. AAV vectors have emerged as the industry's preferred platform for introducing therapeutic genes into target cells due to their safety profile, broad tissue tropism, and ability to transduce both dividing and non-dividing cells. These vectors can be engineered to target specific organs or cell types, making them invaluable for treating genetic disorders, neurological conditions, and certain cancers.

The gene therapy sector has witnessed explosive growth in AAV-based therapeutics, with multiple approved treatments demonstrating transformative clinical outcomes. Manufacturing AAV vectors at commercial scale presents significant technical challenges, including achieving consistent yields, ensuring vector purity, and managing production costs that can exceed millions per patient dose. Biopharmaceutical companies invest heavily in developing proprietary AAV serotypes with enhanced targeting capabilities and reduced immunogenicity. The competitive landscape includes specialised CDMOs offering AAV manufacturing services, while pharmaceutical innovators focus on capsid engineering and novel delivery strategies. Understanding AAV biology, manufacturing complexities, and regulatory considerations proves essential for stakeholders in the rapidly advancing cell and gene therapy ecosystem.